[4-[3-[(4-Methyl-1,3-benzothiazol-2-yl)carbamoyl]-5-propan-2-yloxyphenoxy]phenyl]phosphonic acid | 1119776-70-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [4-[3-[(4-Methyl-1,3-benzothiazol-2-yl)carbamoyl]-5-propan-2-yloxyphenoxy]phenyl]phosphonic acid
• CAS: 1119776-70-3
• 化学式: C₂₄H₂₃N₂O₆PS
• 分子量: 498.496
• InChiKey: YNNAUQFXXIXUAL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  146
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• NOVEL ACTIVATORS OF GLUCOKINASE
  申请人：Metabasis Therapeutics, Inc.

  公开号：US20150119365A1

  公开（公告）日：2015-04-30

  The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

  本发明提供了式I和式II的新化合物，以及其药学上可接受的盐和共晶体，具有葡萄糖激酶激活剂活性。本发明还提供了包含这些化合物的药物组合物，以及治疗、预防、延迟发病时间或降低发展或进展一种或多种葡萄糖激酶激活剂所指示的疾病或状况的方法，包括1型和2型糖尿病、糖耐量受损、胰岛素抵抗和高血糖。本发明还提供了制备式I和式II的化合物，包括其盐和共晶体的方法，以及包含这些化合物的药物组合物的制备方法。
• Activators of glucokinase
  申请人：Metabasis Therapeutics, Inc.

  公开号：US10174062B2

  公开（公告）日：2019-01-08

  The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

  本发明提供了具有葡萄糖激酶激活剂活性的式 I 和式 II 的新型化合物及其药学上可接受的盐和共晶体。本发明进一步提供了包含上述化合物的药物组合物，以及治疗、预防、延缓发病时间或降低一种或多种葡萄糖激酶激活剂适用的疾病或病症（包括 1 型和 2 型糖尿病、糖耐量受损、胰岛素抵抗和高血糖症）的发生或发展风险的方法。本发明还提供了制造式 I 和式 II 化合物（包括其盐和共晶体）的工艺，以及包含这些化合物的药物组合物。
• US9522926B2
  申请人：——

  公开号：US9522926B2

  公开（公告）日：2016-12-20